证券代码：688139 证券简称：海尔生物 公告编号：2024-065 青岛海尔生物医疗股份有限公司 重要内容提示： （http://roadshow.sseinfo.com/） 投资者可于 2024 年 9 月 18 日(星期三)16:00 前通过邮件 （haierbiomedical@haierbiomedical.com）、电话（0532-88935566）等方式将需 要了解和关注的问题提前提供给公司。公司将在说明会上对投资者普遍关注的问题 进行回答。 青岛海尔生物医疗股份有限公司（以下简称"公司"）于 2024 年 8 月 23 日发 布公司 2024 年半年度报告，为便于广大投资者更全面深入地了解公司 2024 年半年 度经营成果、财务状况、发展理念，公司参与了由上交所主办的 2024 年半年度科 创板医疗器械及医疗设备专场集体业绩说明会，此次活动将采用网络文字互动的方 式举行，投资者可登录上海证券交易所上证路演中心 （http://roadshow.sseinfo.com/）参与线上互动交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2024 年半年度报告的经 1 关于参 ...

证券代码：688139 证券简称：海尔生物 青岛海尔生物医疗股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|-------------------------|------------------------------------------------------| | | | 编号： 2024-017 | | 投资者关系活动 | R | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 □电话会议 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 | | 诚通国调基金、淳厚基金、东吴证券、工银安盛人寿、泓德 | | | | 基金、华泰基金、交银施罗德基金、民生加银基金、诺安基 | | | | 金、西南证券、新华基金、兴业基金、招银理财、中金公 | | | | 司、中信保诚基金、中信建投证券共 16 家机构 | | 时间 | 2024 年 8 月 28 | 日-2024 年 8 月 29 日 | | 参会方式 | 电话会 ...

Investment Rating - The investment rating for the company is "Buy-A" with a target price of 31.56 CNY over the next six months [1][6]. Core Views - The company experienced a temporary decline in performance due to short-term factors, but new industries continue to grow rapidly [2][3]. - The life sciences segment showed a revenue increase of 2.28% year-on-year, while the new industries segment saw a significant growth of 22.69% year-on-year, contributing to 42.63% of total revenue [3][4]. - The company is expanding its overseas competitiveness, with project business opportunities exceeding 1 billion CNY [4][6]. Financial Performance Summary - In the first half of 2024, the company reported a revenue of 1.223 billion CNY, a decrease of 3.71% year-on-year, and a net profit of 234 million CNY, down 15.84% year-on-year [2]. - The gross margin for the first half of 2024 was 46.57%, a decrease of 5.91 percentage points year-on-year, but adjusted figures show a gross margin of 50.11% [2]. - The company expects revenue growth rates of 10.0%, 25.5%, and 23.7% for 2024, 2025, and 2026, respectively, with net profit growth rates of 23.6%, 21.0%, and 20.4% [6][8]. Business Segment Performance - The life sciences segment's revenue was 607 million CNY in the first half of 2024, with low-temperature storage business facing challenges due to delayed orders [3]. - The new industries segment's revenue growth was driven by automation in medication, laboratory consumables, and digital public health services, with service revenue increasing by 26% year-on-year [3][4]. - The medical innovation segment reported a revenue of 612 million CNY, down 8.97% year-on-year, primarily due to delays in overseas public health project orders [3]. Market Position and Outlook - The company achieved a domestic revenue of 892 million CNY, up 6.93% year-on-year, while overseas revenue was 328 million CNY, down 24.17% due to order delays [4][6]. - The company has established localized teams in over 150 countries, enhancing its competitive edge in overseas markets [6]. - The company has introduced 21 new product models and achieved over 400 certifications, further strengthening its market position [6].

证券代码：688139 证券简称：海尔生物 青岛海尔生物医疗股份有限公司 投资者关系活动记录表 编号：2024-016 | --- | --- | --- | |----------------|-----------------------|------------------------------------------------------| | 投资者关系活动 | R | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □现场参观 □电话会议 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 | Harding Loevner | 、创金合信基金、广发基金、国泰基金、嘉 | | | | 实基金、建信养老金公司、农银汇理基金、鹏华基金、青岛 | | | | 久实投资、施罗德香港、兴业证券、友邦人寿、长安基金、 | | | | 中加基金、中信建投证券、中信资管共 16 家机构 | | 时间 | 2024 年 8 月 26 日 | -2024 年 8 月 27 日 | 参会方式 电话会议 | ...

[ T able_StockInfo] 2024 年 08 月 25 日 证券研究报告•2024 年中报点评 当前价：26.82 元 海尔生物（688139）医药生物 目标价：——元（6 个月） 低温存储收入环比提升，新产业收入同比提升 23% [Table_Summary 事件：公司发布] 2024 年中报，24H1 实现营收 12.2 亿元（-3.7%），归母净利润 2.3亿元（-15.8%），扣非归母净利 2.1亿元（-7.5%）；其中 24Q2营收 5.4亿元 （-8.1%），归母净利润 0.97亿元（-31.4%），扣非归母净利润 0.79亿元（-24.4%）。 业绩收入略有承压。分季度看，2024Q1/Q2 单季度收入分别为 6.9/5.4 （+0%/-8.1%），单季度归母净利润分别为 1.4/0.97亿元（+0.1%/-31.4%）。24H1 受低温存储行业疲软和用户订单延迟等因素影响，收入略有承压。从盈利能力来 看，24H1毛利率 48.3%，毛利率有所下滑主要原因为执行财政部新会计准则导 致会计政策变更，保证类质保费用计入营业成本所导致，若按同口径还原公司毛 利率为 50.11%。从费用率 ...

Investment Rating - Buy (Maintained) [1] Core Views - The company's overseas projects are under pressure due to delays in the execution of solar vaccine solution orders, leading to a 50% decline in storage-related business [2] - Excluding the impact of the solar vaccine solution, the company's low-temperature storage business remained flat compared to the same period last year [2] - The company's non-storage revenue grew by 22.7% YoY in H1 2024, accounting for 42.6% of total revenue [2] - The company's gross margin in H1 2024 was 48.3%, but would have been 50.1% if adjusted for the new accounting standards [2] - The company's revenue and net profit in H1 2024 showed positive marginal changes, with revenue increasing by 21% QoQ and net profit increasing by 84% QoQ [3] - The company's overseas business in Europe and Asia-Pacific grew by over 30% YoY in H1 2024, excluding the impact of the solar vaccine solution [3] - The company's domestic public health and plasma station digital services are recovering, with over 400 new vaccination sites established [3] Financial Forecasts and Valuation - Revenue for 2024E, 2025E, and 2026E is forecasted to be 2,628 million, 3,127 million, and 3,674 million respectively, with YoY growth rates of 15.2%, 19.0%, and 17.5% [1] - Net profit attributable to the parent company for 2024E, 2025E, and 2026E is forecasted to be 508.83 million, 631.41 million, and 755.06 million respectively, with YoY growth rates of 25.31%, 24.09%, and 19.58% [1] - EPS for 2024E, 2025E, and 2026E is forecasted to be 1.60, 1.99, and 2.37 respectively [1] - The current P/E ratio is 17.86x for 2024E, 14.39x for 2025E, and 12.03x for 2026E [1] Business Performance - In H1 2024, the company's revenue was 1,223 million (-3.7% YoY), with net profit attributable to the parent company of 234 million (-15.8% YoY) [2] - In Q2 2024, the company's revenue was 536 million (-8.12% YoY), with net profit attributable to the parent company of 97 million (-31.4% YoY) [2] - The company's life science business revenue in H1 2024 was 610 million (+2.3% YoY), while the medical innovation business revenue was 610 million (-9.0% YoY) [2] - Domestic revenue in H1 2024 was 892 million (+6.9% YoY), while overseas revenue was 330 million (-24.2% YoY) [2] Market Data - The closing price of the company's stock is 28.58 yuan [5] - The company's market capitalization is 9,087.08 million [5] - The P/B ratio is 2.14x [5]

证券代码：688139 证券简称：海尔生物 公告编号：2024-062 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 青岛海尔生物医疗股份有限公司 2024 年半年度募集资金存放与使用情况专项报告 1 | 项目 | | | | | | 金额（人民币元） | | --- | --- | --- | --- | --- | --- | --- | | 2019 月 22 | 年 10 | | | | 日实际到账的募集资金 | 1,161,576,074.14 | | 减：支付的其他发行费用 | | | | | | 4,670,375.54 | | 减：募投项目支出金额 | | | | | | 894,181,404.49 | | 减：永久补充流动资金 | | | | | | 77,550,000.00 | | 减：期末用于现金管理的暂时闲置募集资 金金额 | | | | | | 230,000,000.00 | | 加：募集资金现金管理产品累计收益金额 | | | ...

Financial Performance - The company's operating revenue for the first half of 2024 was CNY 1,223,284,970.75, a decrease of 3.71% compared to CNY 1,270,455,870.90 in the same period last year [14]. - The net profit attributable to shareholders of the listed company was CNY 234,342,835.01, down 15.84% from CNY 278,462,841.61 in the previous year [14]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 211,750,860.17, a decrease of 7.52% compared to CNY 228,979,648.23 last year [14]. - The net cash flow from operating activities was CNY 59,276,033.76, a significant decline of 47.81% from CNY 113,580,161.42 in the same period last year [14]. - Basic earnings per share for the reporting period (January to June) decreased to 0.74 CNY, down 15.91% from 0.88 CNY in the same period last year [15]. - The weighted average return on equity fell to 5.49%, a decrease of 1.30 percentage points compared to 6.79% in the previous year [15]. - The company's gross profit margin for the first half of 2024 was 48.27%, with a restored margin of 50.11% when adjusted for accounting policy changes [57]. - The net profit attributable to shareholders decreased year-on-year but increased by 84% compared to the second half of last year, with a net profit margin of 19.16% [57]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,586,721,674.79, reflecting a growth of 1.10% compared to CNY 5,525,682,568.67 at the end of the previous year [14]. - The net assets attributable to shareholders at the end of the reporting period were CNY 4,254,327,364.48, an increase of 0.56% from CNY 4,230,710,929.50 at the end of the previous year [14]. - The company's total liabilities were CNY 1,089,154,649.51, slightly up from CNY 1,085,719,569.95 [118]. - Shareholders' equity increased to CNY 4,497,567,025.28 from CNY 4,439,962,998.72, reflecting a growth of about 1.3% [118]. - Accounts receivable increased by 108.73% to CNY 391,743,373, representing 7.01% of total assets, attributed to increased revenue from new medical infrastructure projects [79]. - The company's financial assets decreased by 38.19% to CNY 402,494,537, accounting for 7.20% of total assets [79]. Research and Development - Research and development expenditure accounted for 11.73% of operating revenue, down 0.67 percentage points from 12.40% in the same period last year [15]. - The total R&D investment amounted to ¥143,448,942.59, a decrease of 8.96% compared to ¥157,574,507.09 in the same period last year, representing 11.73% of operating revenue [45]. - The company has developed six major technology platforms and holds a total of 1,541 patents, indicating a strong focus on innovation and technology leadership [20]. - The company has applied for 142 new patents and software copyrights during the reporting period, obtaining 212, including 24 new invention patents, bringing the total to 1,541 patents and 348 software copyrights [42]. Market and Industry Trends - The global life science tools market is projected to reach $161.57 billion in 2023 and $330.69 billion by 2030, with a compound annual growth rate (CAGR) of 10.8% [25]. - The life sciences and medical innovation sectors are experiencing significant growth due to increased demand for comprehensive solutions in biological experiments, drug development, and medical services [24]. - The demand for medical equipment replacement is estimated to be around CNY 130 to 150 billion, with a market growth rate expected to exceed 6% due to policy-driven demand [28]. - The penetration rate of smart laboratories in China's life sciences sector is currently below 20%, indicating significant growth potential [31]. Corporate Governance and Compliance - The report was not audited, and the management has confirmed the accuracy and completeness of the financial statements [4]. - The company has outlined various risks and countermeasures in the report, which can be found in the "Management Discussion and Analysis" section [3]. - There were no significant non-operating fund occupations by controlling shareholders or related parties [4]. - The company has not faced any administrative penalties due to environmental issues during the reporting period [87]. Environmental and Social Responsibility - The company has integrated green and innovative development concepts into product design, achieving multiple national energy-saving and environmental certifications [88]. - The company has been recognized as a "National Green Factory" and a "Low-Carbon Demonstration Enterprise" in Qingdao [88]. - The company reduced carbon dioxide equivalent emissions by 60 tons through measures such as using clean energy [89]. - The company actively participates in biodiversity protection and the construction of a global ecological community [88]. Future Outlook and Strategic Initiatives - The company is focusing on digital scene solutions in life sciences and medical innovation, improving efficiency and safety in laboratory and medical settings [54]. - The company is developing a new automated drug management system, with a focus on smart management solutions for hospitals and laboratories [49]. - The company has initiated new strategies for market expansion, although specific details were not disclosed in the report [136]. - The company is actively expanding its overseas sales channels to mitigate risks associated with regulatory changes in the medical device industry [76].

证券代码：688139 证券简称：海尔生物 公告编号：2024-061 青岛海尔生物医疗股份有限公司 关于执行新会计准则导致会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 重要内容提示： 一、会计政策变更情况概述 （一）变更原因 财政部于 2024 年 3 月发布《企业会计准则应用指南汇编 2024》，规定保证 类质保费用应计入营业成本。据《企业会计准则应用指南汇编 2024》的规定,公 司需对原采用的相关会计政策进行相应调整。 （二）变更的日期 公司自 2024 年 1 月 1 日起执行上述会计准则，对相关的会计政策进行变更。 （三）变更前后采用的会计政策 本次会计政策变更前，公司执行财政部发布的《企业会计准则——基本准则》 1 本次会计政策变更为青岛海尔生物医疗股份有限公司（以下简称"公司"） 根据中华人民共和国财政部（以下简称"财政部"）发布的《企业会计 准则应用指南汇编 2024》而进行的相应变更，无需提交公司董事会、监 事会和股东大会审议。 本次变更不会对公司的财务状况、经营成果和现金流量产 ...

证券代码：688139 证券简称：海尔生物 公告编号：2024-063 青岛海尔生物医疗股份有限公司 第三届监事会第二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、监事会会议召开情况 青岛海尔生物医疗股份有限公司（以下简称"公司"、"本公司"或"海尔 生物"）第三届监事会第二次会议于 2024 年 8 月 22 日下午 14:00 以现场结合通 讯方式召开，现场会议在青岛市高新区丰源路 280 号海尔生物医疗新兴产业园办 公楼 101 会议室举行。本次会议的通知于 2024 年 8 月 9 日以电子邮件方式送达 全体监事。本次会议应出席监事 3 人，实际出席监事 3 人，会议由江兰主持。会 议的召集和召开程序符合有关法律法规、规范性文件和公司章程的规定，会议决 议合法、有效。 二、监事会会议审议情况 本次会议由江兰主持，经全体监事认真审议并表决，本次会议通过了如下议 案： （一） 审议通过《关于审议公司 2024 年半年度报告及摘要的议案》 表决结果：3 票赞成，0 票弃权，0 票反对。 （二）审议 ...